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Abstract 
This study investigates possible effects of in utero exposure of rats to a low dose (125 
mg/kg bw/day) and a high dose (750 mg/kg bw/day) of Diisononyl phthalate (DINP) 
during the masculinisation programming window (MPW) which is embryonic days 15.5 
to 18.5 (e15.5 - e18.5). Dibutyl phthalate (DBP) was used at a high dose level (750 
mg/kg bw/day) as an established positive control substance for anti-androgenic effects 
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We focussed on the MPW and measured a multitude of biological endpoints at various 
life stages and applied state of the art histopathology staining techniques to refine the 
characterization of potential changes to the testis, beyond what is currently available 
with DINP. If DINP can mediate testicular dysgenesis (TDS) disorders, this exposure 
window would be sufficient to induce androgen impacts and alter male reproductive 
tract development as shown earlier in this validated experimental model with DBP. 
Overall, the results of this systematic comparison provide convincing evidence on the 
differences between the effects occurring with DBP and DINP. In contrast to what was 
seen with DBP, DINP did not cause cryptorchidism or hypospadias, had no effect on 
anogenital distance/anogenital index (AGD/AGi) and Leydig cell aggregates on e17.5 
and e21.5 did not increase. With DINP no reduction of intratesticular testosterone, no 
effects on sperm motility and sperm count and no effect on adult testosterone or 
luteinizing hormone (LH) levels were seen. Our results demonstrate that DINP does 
not cause the adverse reproductive effects known to occur with DBP, a well-
established endocrine disruptor. 
 
Keywords 
- Diisononyl phthalate (DINP) 
- Dibutyl phthalate (DBP) 
- Endocrine disruption 
- Sperm parameters 
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Abbreviations 
AGD: Anogenital distance 
AGi: Anogenital distance normalized to body weight 
AUCinf: Area under the concentration curve extrapolated to infinity 
BSA: bovine serum albumin 
Cmax: maximum concentration 
DBP: Dibutyl phthalate 
DINP: Diisononyl phthalate 
e day: embryonic day (e1=GD1; gestational day 1) 
3β-HSD: 3- -hydroxysteroid dehydrogenase; Leydig cell marker 
HMW: high molecular weight phthalate; all with straight carbon chain length of 
  the esterified alcohols ≥7 
GD: gestational day (GD1=e1; embryonic day 1) 
NCS: normal chicken serum 
NGS: normal goat serum 
LMW: low molecular weight phthalate; straight chain length of the esterified 
 alcohols between 3 and 6 carbon atoms  
MPW: masculinisation programming window 
PBS: phosphate buffered saline 
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SMA: -smooth muscle actin; peritubular myeloid cell marker 
Sox-9: gene mainly expressed in Sertoli cells; Sertoli cell marker 
TBS: Tris buffered saline 
TDS: Testicular Dysgenesis Syndrome 
 
1. Introduction 
Formation of a testis and its subsequent production of androgens in early fetal life are 
prerequisites for masculinisation (Scott et al., 2009). Any disruption of these events 
can have adverse consequences and lead to common reproductive disorders that 
manifest already at birth, in puberty or in adulthood - this has been summarised in the 
testicular dysgenesis syndrome (TDS) hypothesis (Skakkebaek et al., 2001). A rat 
model of TDS has been developed and validated involving in utero exposure to Dibutyl 
phthalate (DBP) (Fisher et al., 2003; Kilcoyne et al., 2014; van den Driesche et al., 
2012). DBP is a low molecular weight phthalate (LMW) with a straight carbon chain 
length in the esterified alcohols of 4 carbons (Table 1). DBP is classified and labelled 
accordingly as toxic to reproduction and is an established positive control substance 
for androgen disruption during this period of male fetal development. In utero exposure 
to DBP at a time which includes the so-called masculinisation programming window 
(MPW; embryonic day e15.5-e18.5), results in impaired androgen production, late-
onset focal testicular dysgenesis and downstream male reproductive tract 
malformations (Carruthers et al., 2005; MacLeod et al., 2010; van den Driesche et al., 
2017; Welsh et al., 2008). Recently it was demonstrated that DBP exposure 
specifically only in the MPW is necessary and sufficient to induce suppression of fetal 
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(manifesting as malformed seminiferous tubules and abnormal distribution of somatic 
cells in focal areas) and TDS disorders such as cryptorchidism, hypospadias, reduced 
adult testis size, and compensated adult Leydig cell failure (van den Driesche et al., 
2017). Reduced androgen production in this small critical window of time during 
development is considered central to these changes, but exactly how, and its 




Exposure of rats to other LMW phthalates (e.g. Diisobutyl phthalate (DIBP) and Di-
(2-ethylhexyl) phthalate (DEHP)) has been shown to disrupt sexual development in 
male offspring following exposure during the MPW in a manner similar to DBP 
(Saillenfait et al., 2006, 2008, 2011; Wolfe et al., 2005). Based on the collective data 
for the LWM phthalates, it is considered that phthalates with straight carbon chain 
lengths in the esterified alcohols between 3 and 6 form the active cluster for toxicity 
to reproduction, with testicular toxicity being the most sensitive endpoint (Fabjan et 
al., 2006). The ability of the high molecular weight (HMW) phthalate Diisononyl 
phthalate (DINP) with straight carbon chain lengths of ≥7 in the esterified alcohols to 
similarly disrupt development of the male reproductive tract and lead to TDS 
disorders is not well supported by existing data ( ECHA, 2013, ECHA RAC 2018; 
NICNAS, 2015). 
 
DINP is a member of the category of HMW phthalates and is a complex mixture of 
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commerce: 1,2-Benzenedicarboxylic acid esterified with branched alcohols 
consisting of C8-C10 (C9 rich) alkyl side chains (CAS No 68515-48-0), also referred 
to as DINP1, and DINP2 (CAS No 28553-12-0), esterified with alcohols of strictly C9 
branched and linear alkyl side chains (EU RAR, 2003; Koch et al., 2012). In DINP1 
the alcohols typically consist of dimethyl heptanols branched at diverse positions and 
15-25% isodecanols (Waterman et al., 1999). In DINP2 the predominant C9-isomers 
are identified as methyl octanols and dimethyl heptanols, and 10% of the linear n-
nonanol. For DINP, liver toxicity in rodents is identified to be the most sensitive 
endpoint (EFSA, 2005, 2019; ECHA RAC 2018) and accordingly, EFSA has based 
their derived tolerable daily intake (TDI) on this endpoint. It has been suggested that 
liver toxicity is indirectly linked to transient reductions of testicular testosterone 
(ECHA RAC 2018; Dekant, 2020), but DINP is shown to be less potent than DBP 
(Clewell et al., 2013b; Furr et al., 2014) in reducing testicular testosterone. Available 
studies involving exposure to either DINP1 or DINP2 during the MPW collectively 
show marked differences in the extent, severity and incidence of effects when 
compared to similar doses of DBP. The studies on DINP have consistently reported 
a lack of induction of gross male reproductive tract malformations such as 
cryptorchidism and hypospadias (Boberg et al., 2011; Clewell et al 2013b; Gray et 
al., 2000). Likewise, DINP has been shown to have no impact on general 
reproductive tract development manifested as decreased relative weights in 
androgen sensitive tissues: levator ani/bulbocavernosus muscles (LABC), seminal 
vesicles, ventral prostrate, glans penis, bulbourethral gland, and epididymis (Boberg 
et al., 2011; Gray et al., 2000; Clewell et al., 2013b). 
Despite the collective evidence demonstrating DINP does not induce TDS disorders, 
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developing fetus (Borch et al., 2004; Clewell et al., 2013a; Furr et al., 2014; Hannas 
et al., 2011;), albeit at much higher doses than DBP, spurred regulatory questions 
regarding the potential of DINP to disrupt male reproductive tract development 
(CPSC, 2018; ECHA, 2013; EFSA, 2019). The ECHA Risk Assessment Committee 
(RAC) undertook a thorough in-depth assessment of the DINP database and 
concluded (ECHA RAC 2018) no classification for DINP for either effects on sexual 
function and fertility, or for developmental toxicity is warranted (according to 
European CLP (classification, labelling and packaging of substances) Regulation 
(EC) No 1272/2008, the EU implementation of the Globally Harmonized System 
(GHS)). Despite this official regulatory conclusion from ECHA determining absence 
of DINP mediated adverse effects on reproduction and development, some views 
continue to suspect DINP of causing adverse effects on male reproductive 
development through an endocrine mode of action. 
While the morphological signs of TDS disorder emerge in the rat after the MPW, the 
mechanistic changes necessary for mediating the disorder are induced (i.e. 
programmed) by exposure in the MPW (van den Driesche et al., 2017). That is to 
say that DBP induction of comparable testosterone deficiency due to exposure after 
the MPW (GD19.5-20.5) does not induce TDS disorders, nor does more prolonged 
DBP exposure (GD 13.5-21.5) induce any greater incidence of TDS disorders than 
just treatment during the MPW (van den Driesche et al. 2017). All of the existing 
studies assessing DINP effects on in vivo testosterone levels in fetal testes measure 
impacts at a gestational time point subsequent to the MPW. Because impacts on 
androgen production during -and not after- the MPW (Carruthers et al., 2005; Foster 
et al., 2001; Welsh et al., 2008; van den Driesche et al., 2017) are central to TDS 
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18.5) in an in vivo model is important for reconciling the dataset for DINP. 
Additionally, we were interested in assessing if changes induced during the MPW 
alone manifested into focal areas of testicular dysgenesis, similar to what has been 
seen with DBP (van den Driesche et al., 2012, 2017). 
In this study we investigated effects of in utero exposure to a low dose (125 mg/kg 
bw/day) and a high dose (750 mg/kg bw/day) of DINP during the MPW (i.e. e15.5-
e18.5 only) and compared the results with a high dose (750 mg/kg bw/day) DBP 
exposure using similar read-outs as published by van den Driesche et al., 2017. The 
high dose level of DINP (750 mg/kg bw/day) was considered appropriate based on 
the observation of significant reductions of maternal body weight changes as signs of 
moderate maternal toxicity at this dose in published studies (Hellwig et al., 1997; 
Masutomi et al., 2003); and the recognition that impacts on testes testosterone levels 
and steroidogenic gene transcription have been reported at this dose of DINP and 
lower (Borch et al., 2004; Clewell et al., 2013a; Furr et al., 2014; Hannas et al., 2011, 
2012). Saturation of DINP metabolism and significant changes of kinetics occur 
between the DINP dose levels of 250 mg/kg bw/day and 750 mg/kg bw/day, where 
despite a 3-fold increase in dose, Cmax and AUCinf did not increase (Clewell et al., 
2013a). Deviation from linearity and saturation of metabolism at 750 mg/kg bw/day 
was also noted in the recently developed PBPK model for DINP (Campbell et al., 
2020). We narrowed the exposure window to e15.5-e18.5 to focus on the critical 
question of DINP s potential anti-androgenic impacts on the developing male 
reproductive tract and measured both hormone levels and impacts on 
steroidogenesis at various life stages and applied state of the art histopathology 
staining techniques to refine the characterization of potential changes to the testis 
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disorders, this exposure window, as validated with DBP which is used here as a 
positive control in this experimental model, would be sufficient to induce androgen 




2. Materials and Methods 
 
2.1. Ethics Statement 
We treated the animals used in this study humanely and according to the Animal 
(Scientific Procedures) Act 1986 and approval by the UK Home Office. Studies were 
conducted under Project License (PPL P5B09956A) following review by the 
University of Edinburgh Animal Research Ethics Committee. 
 




Time-mated female Wistar rats (Harlan, UK) were housed for a minimum of 1 week in 
ventilated cages (2000P cages; Tecniplast, Buguggiate, Italy) prior to use in 
experimental studies and were kept under standard conditions with ad libitum access 
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Housing conditions were carefully controlled (lights on at 07:00, off at 19:00, 
temperature 19–21° C, humidity 45-65%, GOLD shavings and LITASPEN standard 
bedding (SPPS, Argenteuil, France)). The dams were allocated randomly to receive 
vehicle control (corn oil; Sigma-Aldrich Company Ltd) treatment, 750 mg/kg bw/day 
Dibutyl phthalate (DBP; Sigma-Aldrich Company Ltd, Dorset, UK; 99% pure (GC 
area%) according to the supplier), 125 mg/kg bw/day or 750 mg/kg bw/day Diisononyl 
phthalate (DINP2; BASF SE, Germany, purity: ≥99.5% (GC area%)) in 1 ml/kg corn 
oil, daily by oral gavage. The dose of DBP was based on our previous study (van den 
Driesche et al., 2017) The high dose DINP was based on considerations of maternal 
toxicity (Hellwig et al., 1997; Masutomi et al., 2003), toxicokinetics (Campbell et al., 
2020; Clewell et al., 2013a) and dose effect levels in prior studies reporting effects on 
molecular endpoints assessed herein (Borch et al., 2004; Clewell et al., 2013a; Furr 
et al., 2014; Hannas et al., 2011, 2012). All treatments were performed in a single 
animal facility at the University of Edinburgh and treatments were administered 
between 09:00-10:30 during the masculinisation programming window treatment 
(MPW; e15.5-e18.5). Male fetuses were collected at e17.5 (within the MPW), e21.5 
(at the end of gestation) or at postnatal day 90 (adulthood). Pregnant dams were killed 
by CO2 inhalation followed by cervical dislocation. Fetuses were removed, decapitated 
and placed in ice-cold PBS (Sigma-Aldrich). Post-natal animals were housed with their 
natural mothers from birth or in cages with a maximum of 6 animals after weaning and 
were killed by CO2 inhalation followed by cervical dislocation. Fetal testes were 
removed by microdissection and fixed in Bouin s fixative for 1 hour, transferred to 70% 
(v/v) ethanol and then processed into paraffin blocks using standard procedures. 
Testes from the fetuses used for intratesticular testosterone measurements and adult 
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2.3. Adult phenotypical analysis 
When the adult male rats were collected, their body weight was measured and they 
were subjected to a detailed inspection to determine testicular descent and the 
normality of the penis. Hypospadias and cryptorchidism were examined as described 
previously (Welsh et al., 2008; van den Driesche et al., 2017). Anogenital distance 
(AGD) was measured prior to opening of the abdomen, using digital callipers (Faithfull 
Tools, Kent, UK), as was the length of the penis after being dissected out. Anogenital 
Index (AGi) was calculated to normalize to pup or adult body weight (i.e. AGi was 
calculated by dividing AGD by the cube root of body weight). The testes, ventral 
prostate and seminal vesicles were also dissected out and weighed. 
 
2.4. Adult sperm motility and sperm head count 
The testis and cauda epididymis were taken from all groups and sperm motility, 
sperm morphology, sperm head count (cauda epididymis) and sperm head count 
(testis) were determined. Sperm motility examinations were carried out in a 
randomized sequence using the sperm from the cauda epididymis. For sperm 
motility the numbers of observations are: vehicle control (27 from 7 litters), 750 
mg/kg bw/day DBP (DBP-750; 17 from 6 litters), 125 mg/kg bw/day DINP (DINP-125; 
36 from 7 litters), 750 mg/kg bw/day DINP(DINP-750; 28 from 7 litters). Numbers for 
sperm head counts were the same for vehicle control and DINP groups, but different 
for the DBP-750 group (26 from 6 litters) because a number of adults treated with 
750 mg/kg bw/day DBP had epididymal agenesis or missing epididymis. Sperm 
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and sperm head counts were similarly done according to previously published 
studies (Meistrich, 1989). In brief, the tunica albuginea was opened with a scalpel 
and the parenchym of the testis was isolated and weighed. The samples were 
refrigerated in a solution of 0.1 % Triton X-100 (Merck) and stored at -20° C until 
further processing. After thawing, the samples were homogenized in randomized 
order for 30 seconds with a Polytron at 20 000 U/min, the homogenates were 
collected through a Nylon sieve and the residual content in the sieve was washed 
twice with water. The homogenization resistant spermatids were kept on a magnetic 
stirrer running at low velocity until counting. 3 µl of the solution were counted in the 
MAKLER chamber (20-fold magnification, counting of 100 squares) and the mean 
value of 3 chambers counted per animal was taken.  
 
2.5. Triple imm nofl ore cence for Smoo h M cle Ac in, 3 -HSD and Sox-9 
Fetal testes were removed by microdissection and fixed in Bouin s fixative for 1 hour, 
transferred to 70% (v/v) ethanol and then processed into paraffin blocks using 
standard procedures. Sampling at the different time points was as follows: 
E17.5: Control: n = 15 from 6 litters, DBP-750: n = 15 from 6 litters, DINP-125: n = 15 
from 6 litters, DINP-750: n = 15 from 5 litters. 
E21.5: Control: n = 15 from 6 litters, DBP-750: n = 15 from 5 litters, DINP-125: n = 15 
from 5 litters, DINP-750: n = 15 from 6 litters. 
We aimed for 15 males for each timepoint by selecting 3 males per litter. In cases 
where there were only 2 males available in a litter, we completed the number of 
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In order to visualize focal dysgenesis, specific antibodies were used for co-
immunolocalisation of 3 -HSD (Leydig cell marker; antibodies-online.com), Sox-9 
(Sertoli cell marker; Chemicon International, UK) and -smooth muscle actin ( -SMA, 
peritubular myoid cell marker; Sigma-Aldrich, UK). Slides were washed between all 
incubation steps in Tris Buffered Saline (TBS) pH 7.6 (3 x 5 min) and all incubations 
were carried out in a humidity box (Fisher Scientific, UK). Sections were dewaxed and 
rehydrated using standard procedures, followed by a peroxidase block in 3% (v/v) 
H2O2 in methanol for 30 minutes. Next, the sections were blocked in normal goat 
serum (NGS; Vector Laboratories Inc, USA) diluted 1:5 in TBS containing 5% (w/v) 
bovine serum albumin (BSA) (Sigma-Aldrich; NGS/TBS/BSA), followed by incubation 
with the first primary rabbit antibody, anti-Sox-9, which was diluted 1:1,000 in 
NGS/TBS/BSA overnight at 4° C. The next day, sections were incubated with 
peroxidase-conjugated goat F(ab) anti-rabbit secondary antibody (GARP; Abcam UK), 
diluted 1:200 in NCS/TBS/BSA for 30 minutes at room temperature (RT), and followed 
by incubation with Tyr-Cy3 (Perkin Elmer-TSA-Plus Cyanine3 System; Perkin Elmer 
Life Sciences, USA) according to the manufacturer s instructions. From here onwards 
slides were kept in the dark. Next, the sections were subjected to antigen retrieval by 
boiling in a pressure cooker in 0.01 mol/l citrate buffer (pH 6.0) for 5 minutes and left 
to cool for 20 minutes. This was followed by another block in NGS/TBS/BSA and 
overnight incubation at 4q C with the second primary antibody, rabbit anti-3 -HSD, 
diluted 1:1,000 in NGS/TBS/BSA. On the third day, slides were incubated with 
peroxidase-conjugated goat F(ab) anti-rabbit secondary antibody (Abcam) diluted 
1:200 in NGS/TBS/BSA for 30 minutes at RT, followed by incubation with Tyr-fl (Perkin 
Elmer-TSA-Plus Fluorescein System; Perkin Elmer Life Sciences) according to the 
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(v/v) H2O2 in TBS plus 0.01% (v/v) Tween-20 (Sigma-Aldrich) for 20 minutes followed 
by blocking in NGS/TBS/BSA and overnight incubation at 4q C with the third primary 
antibody, mouse anti-SMA, diluted 1:10,000 in NGS/TBS/BSA. On the last day, 
sections were incubated with peroxidase-conjugated goat F(ab) anti-mouse 
secondary antibody (Abcam) diluted 1:200 in NGS/TBS/BSA for 30 minutes at RT, 
and followed by incubation with Tyr-Cy5 (Perkin Elmer-TSA-Plus Cyanine5 System; 
Perkin Elmer Life Sciences, Boston, MA, USA) according to the manufacturer s 
instructions. Finally, the slides were mounted with Permafluor (Thermo Scientific, UK) 
and fluorescent images were captured using a Nikon A1R confocal laser microscope.  
 
2.6. Hormone measurements 
Adult male animals were sacrificed by CO2 inhalation followed by cervical dislocation 
and straight after that blood was collected from the heart and stored on wet ice. Plasma 
was collected by centrifugation of all samples collected at the day of sacrifice. Fetal 
testes were homogenised in 250 L ice cold PBS using a handheld tissue 
homogeniser (Thomas Scientific). The homogenates were centrifuged at full-speed 
and the supernatant was used for intratesticular testosterone measurements as 
described below. Fetal intratesticular testosterone, adult plasma testosterone and LH 
measurements were done by the Specialised Assay Laboratory at the MRC Centre for 
Reproductive Health, Edinburgh, UK. The testosterone ELISA was performed by 
coating 96-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) with 100 µl 
of donkey anti-rabbit IgG (Jackson ImmunoResearch Inc, West Grove, USA) per well 
at a dilution of 1:500 in ELISA coating buffer (100 mM Na Bicarbonate, pH 9.6) covered 
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with wash buffer (0.05 M Tris/HCl + 0.05 % Tween 20, pH 7.4). Next, 250 l of blocking 
buffer (PBS pH 7.4 containing 0.5% BSA) was added to each well and incubated for 
1 hour at room temperature whilst shaking before being washed 2 times with wash 
buffer. Standards, samples and controls (20 µl per well) were added to each well, 
followed by 80 µl of testosterone-HRP conjugate (Astra Biotech GmbH, Berlin, 
Germany) at 1:20,000 in assay buffer (PBS pH 7.4 containing 0.1% BSA and 250 
ng/ml cortisol), followed by 50 l of rabbit anti-testosterone-19 antibody (AMS 
Biotechnology, USA) 1:200,000 in assay buffer. Plates were incubated at room 
temperature for 2 hours on a microtiter plate shaker (IKA®, Schuttler MTS4, IKA 
Labortechnik, Staufen, Germany), then washed 5 times with assay wash buffer and 
120 µl of substrate solution (3,3,5,5-Tetramethylbenzidine, Millipore Corporation, 
Temecula, CA, USA) was added to each well. Plates were incubated at room 
temperature without shaking in the dark. After 20 min., the reaction was stopped by 
adding 80 µl of 2N H2SO4 solution (Sigma-Aldrich Company Ltd., Dorset, UK). Finally, 
plates were read on a plate reader at 450 nm. Plasma LH levels in adult rats were 
measured as described previously (McNeilly et al., 2000). 
Standard curves were prepared with a total of 8 different concentrations (24.3, 8.1, 
2.7, 0.9, 0.3, 0.1 0.03 and 0 ng/ml). Samples, standards and controls were included in 
duplicate. Inter- and intra-assay coefficients of variation (CV) were calculated from two 
controls of low and high testosterone in duplicate in each of eight assays. The inter-
assay CV for low and high pools respectively were 11.4% and 9.1%; the intra-assay 
CV were 8.9% and 5.6%. The lower limit of detection was calculated at 0.2 ng/ml.  
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Measurement of Leydig cell aggregate size in the fetal testis was done as described 
previously (Mahood et al., 2007; van den Driesche et al., 2012). Briefly, testes from 
the different treatment groups (n=15 from 5-6 litters per treatment group) were serially 
sectioned and three representative sections from each testis then selected and 
immunostained for 3 -HSD (antibodies-online.com; 1:500) on a Leica BOND-MAX 
automatic immunostaining machine using the BOND Polymer Refine Detection (Leica, 
UK). The three sections chosen were those corresponding to approximately 25, 50, 
and 75% intervals through the serially sectioned testis. Sections immunostained for 
3 -HSD were not counterstained, so as to provide sufficient homogeneity, high 
contrast, and low background to allow computer-assisted thresholding and 
subsequent computer-assisted counting of Leydig cell (3 -HSD-immuno-positive) 
aggregates and determination of Leydig cell aggregation area. Slides were scanned 
using a Zeiss Axioscan Z1 whole slide scanner at 20x magnification using a Hitachi 
HV-F202SCL camera, following intensity-based tissue detection a 0.2% onion skin 
focusing strategy was applied and slides scanned. Fiji image analysis software was 
used for quantification (Schindelin et al., 2012). A custom macro was designed that 
used thresholding to identify the whole tissue section and quantify total pixel area. A 
Gaussian blur (sigma 2) filter was applied to smooth the images and reduce noise. 
Thresholding was then used within the tissue regions to identify aggregates of 
immuno-positive cells. The 3 -HSD staining permitted the identification of cluster 
borders and the measurement of the total area of each cluster volume was quantified. 
Leydig cell aggregates were expressed as percentage of total Leydig cell area. Leydig 
cell aggregates were then assigned arbitrarily to one of two groups: small aggregates, 
accounting for ≤5% of the total Leydig cell aggregate area per testis, and large 
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per testis. The mean of the measured Leydig cell aggregates per testis per animal was 
then calculated and used for analysis. 
 
2.8. Gene expression analysis 
Total RNA was extracted from e17.5 and e21.5 frozen fetal testes samples (n=9 from 
3 litters per treatment group) using the RNeasy Micro Kit (Qiagen, UK) as per 
manufacturer s instructions. The RNA concentration of each sample was measured 
via Nanodrop and each sample was diluted to 100 ng/ l in RNAse-free water. cDNA 
was then prepared from these dilutions using the Superscript VILO cDNA Synthesis 
Kit (Life Technologies). Quantitative real-time RT-PCR was performed on StepOne 
Plus (Life Technologies). Expression of rat StAR, Cyp11a1, and Cyp17a1 RNA was 
determined using the Roche Universal Probe Library (StAR forward primer: 5 -
TCACGTGGCTGCTCAGTATT-3 , reverse primer: 5 -
GGGTCTGTGATAAGACTTGGTTG-3 , probe number 83 cat. no. 04689062001; 
Cyp11a1 forward primer: 5 -TATTCC- GCTTTGCCTTTGAG-3 , reverse primer 5 -
CACGATCTCCTC- CAACATCC-3 , probe number 9 cat. no. 04685075001; Cyp17a1 
forward primer: 5 -CATCCCCCACAAGGCTAAC-3 , reverse primer: 5 -
TGTGTCCTTGGGGACAGTAAA-3 , probe number 67 cat. no. 04688660001; Roche 
Applied Sciences). Two negative control samples were included, one containing all 
required elements but no RNA sample, and one containing an RNA sample but 
excluding reverse transcriptase enzyme. The expression of each gene was 
normalized using a ribosomal 18S internal control (Applied Biosystems cat. no. 
4308329). All samples were run in triplicate and compared to adult testis control 






































































Values are expressed as mean ± SEM. Comparison of treatment effects used one-
way ANOVA followed by the Bonferroni post test when multiple treatment groups were 
compared. These analyses used GraphPad Prism (version 8; GraphPad Software Inc., 




No generalized adverse effects of the DBP or DINP treatments were observed in the 
exposed females. The litter size or sex ratio was not significantly affected by the 
treatments (data not shown). 
 
3.1. Reproductive tract analysis in adult rats exposed to DBP or DINP during the MPW 
Similar to previously published results (van den Driesche et al., 2017), gestational 
exposure to 750 mg/kg bw/day DBP during the MPW resulted in significant effects in 
adult males on anogenital distance (AGD), anogenital index (AGi), average testis 
weight, penis length, penis weight, ventral prostrate weight and seminal vesicle weight 
(Table 2). In contrast, neither high dose (750 mg/kg bw/day) nor low dose (125 mg/kg 
bw/day) DINP exposure during the MPW resulted in any adverse effects on the male 
reproductive tract in adulthood (Table 2). Likewise, only adult animals exposed to 750 
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a significant reduction in both sperm motility and sperm head count (P<0.001; Figure 
2C and 2D, respectively). 
[Table 2]  
[Figure 2] 
 
3.2. Occurrence of hypospadias and cryptorchidism in adulthood following in utero 
exposure to either DBP or DINP 
Of the adult animals that were exposed in utero to 750 mg/kg bw/day DBP during the 
MPW, 81% presented with cryptorchidism (Figure 2A) and 23% with hypospadias 
(Figure 2B). No cryptorchidism or hypospadias was observed in any adult animals that 
were exposed to either dose of DINP during the MPW (Figures 2A, B). 
 
3.3 Effects of in utero exposure to DBP and DINP during the MPW on testosterone 
and luteinizing hormone production 
Previously we observed induction of compensated Leydig cell function  in adult males 
exposed during the MPW to 750 mg/kg bw/day DBP, as indicated by a statistically 
significant increase in circulating luteinizing hormone (LH) levels and concomitant 
significantly increased LH/testosterone ratio (van den Driesche et al., 2017). In the 
current study, while exposure to 750 mg/kg bw/day DBP resulted in decreased 
testosterone together with increased LH production and concomitant increase in the 
LH/testosterone ratio in adults, the effects did not reach statistical significance. Small 
changes in adult circulating testosterone levels without any effect on LH production 
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However, only when the data were analysed using individual animal values of the 
adults rather than litter means, a small, but statistically significant positive effect of in 
utero exposure to 750 mg/kg bw/day DBP on circulating LH levels was observed, 
resulting in an increased LH/testosterone ratio (P < 0.05; data not shown). Similar to 
the litter mean data, this effect was not observed in either 125 or 750 mg/kg bw/day 
DINP treatment groups when the data were analysed as individual animals (data not 
shown). 
 
3.4. Effects of in utero exposure to DBP or DINP during the MPW on the fetal testis 
We isolated fetuses exposed in utero to either vehicle control, 750 mg/kg bw/day DBP, 
125 or 750 mg/kg bw/day DINP at embryonic day e17.5 and e21.5. Similarly to the 
effects observed in adulthood (Table 2), only exposure to 750 mg/kg bw/day DBP 
during the MPW had significant effects on AGD (P<0.001; Figure 3A), average testis 
weight (P<0.001; Figure 3B), and intratesticular testosterone (P<0.001; Figure 3C) at 
GD21.5, which confirms previously published data (van den Driesche et al., 2012, 
2017). No effects were observed after in utero exposure to either DINP dose. At e17.5 
(towards the end of the MPW) only exposure to 750 mg/kg bw/day DBP, caused a 
significant reduction in intratesticular testosterone production (P<0.001; Figure 3D). 
No effects were observed on intratesticular testosterone production on e17.5 following 





































































  page 21 
 
The quantitative mRNA expression of the steroidogenic synthesis genes StAR, 
Cyp11a1 and Cyp17a1 was significantly reduced after exposure to 750 mg/kg bw/day 
DBP at e17.5 (P<0.05; Figure 4A-C), however at e21.5 this reduction had returned to 
control levels (Figure 4D-F). Exposure to either 125 mg/kg bw/day or 750 mg/kg 
bw/day DINP did not have any effect on StAR, Cyp11a1 and Cyp17a1 expression at 
either e17.5 or e21.5 (Figure 4). 
[Figure 4]  
 
3.5. In utero exposure to DBP, not DINP, during the MPW causes fetal testicular 
dysgenesis 
The fetal testicular morphology was investigated using triple immunofluorescence for 
3 -HSD (fetal Leydig cell marker), Sox-9 (Sertoli cell marker) and SMA (peritubular 
myoid cell marker). Similarly, to what we have described previously (van den Driesche 
et al., 2017), in utero exposure to 750 mg/kg bw/day DBP during the MPW results in 
large dysgenetic areas, which consist of a mixture of fetal Leydig cell aggregations 
and ectopically localized Sertoli cells (Figure 5B, asterisk). Fetal testes isolated from 
fetuses that were exposed to either 125 or 750 mg/kg bw/day DINP during the MPW 





The size of fetal Leydig cell aggregates was systematically analyzed at both e17.5 and 
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bw/day DINP, using similar methods as previously described (Mahood et al., 2007; 
van den Driesche et al., 2012). The fetal testis was serial sectioned and sections at 
roughly 25%, 50% and 75% of the testis were used for automatic immunostaining 
procedures (Figure 6A, B). This allowed for quantification of the 3 -HSD 
immunostained areas using software analysis (see Methods) and thereby a systematic 
determination of testicular dysgenesis in the fetal testis samples. As shown in Figures 
6C and 6D, in utero exposure to 750 mg/kg bw/day DBP resulted in a significant 
reduction in the percentage of small fetal Leydig cell aggregates and a significant 
increase in large fetal Leydig cell aggregates (which is a measurement for testicular 
dysgenesis). At e17.5 and e21.5 either dose of DINP did not result in any significant 
differences in the percentage of small or large Leydig cell aggregates when compared 
with vehicle control exposed animals (Figure 6C, D). Interestingly, we did notice a 
small, but significant effect when we compared the 125 with 750 mg/mg bw/day DINP 
exposure groups at e21.5, with the higher DINP dose reflecting a reduction in small 
and an increase in large fetal Leydig cell clusters at e21.5 when compared with the 





The results of our study support that DINP does not elicit the events necessary and 
sufficient for inducing TDS as seen with DBP such as reduced reproductive organ 
size (testes, prostate, seminal vesicles, penis), cryptorchidism, hypospadias, nor 
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4.1. Exact Timing of the exposure 
Consistent with previously published findings (van den Driesche et al. 2012, 2017), 
our study demonstrates that exposure to DBP within the MPW only results in focal 
dysgenesis that manifests histologically after the MPW and after cessation of DBP 
exposure. This dysgenesis is associated with reduced androgen production in the 
MPW (Figure 3), and associated with effects on the male reproductive tract (Table 2 
and Figure 2) including hypospadias (via disruption of genital tubercle development); 
cryptorchidism (via disruption of testis descent); and reduction in AGD and AGi that 
is maintained into adulthood (via disruption of androgen mediated proliferation/cell 
migration of perineal tissue). The temporal mismatch between inhibition of 
steroidogenesis in the MPW and the manifestation of the abnormal testicular 
histopathology days later, indicates that DBP induces focal dysgenesis via a 
programming  that occurs during the MPW. However, it is well established that the 
temporal window of importance for androgen in mediating male reproductive 
development extends beyond the MPW and DBP has been shown to reduce 
testosterone following exposures initiated after the MPW (van den Driesche et al., 
2012). In this study we aimed to untangle the events mediated during the MPW from 
those initiated or impacted later in development by focusing attention on the ability of 
DINP to induce focal dysgenesis via the programming  and steroidogenesis impacts 
that occur during the MPW. Studies assessing effects of DINP on male reproductive 
tract development (Figure 7) have reported effects on testosterone (Borch et al., 
2004; Clewell et al., 2013a; Furr et al., 2014; Hannas et al., 2011) and 
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Li et al., 2015) at doses of 750 mg/kg bw/day and lower, and Leydig cell aggregates 
at doses as low as 300 mg/kg bw/day (Clewell et al., 2013b). If indeed DINP is a 
lower potent inducer of testicular dysgenesis it was reasonable that exposure to 750 
mg/kg bw/day during this necessary and sufficient window of exposure would lead to 
detectable molecular effects at e17.5 and cellular effects at e21.5. Failure to observe 
any effects of DINP using the sensitive techniques employed herein, suggests that 
DINP is unable to induce TDS through a similar programming  mechanism as DBP.  
DEHP and DBP have been shown to also impact rat development in OECD guideline 
developmental toxicity studies (i.e. OECD TG414) in which exposures stop prior to 
the MPW, i.e. exposures during GD6-15 per the former OECD TG414 as published 
in 1981 (the guideline was modified in 2001 to include exposures extending beyond 
organogenesis). Effects in these developmental toxicity studies are not specific to 
the male reproductive tract but also include malformations such as neural tube 
defects and cleft palate. Studies with DINP (Figure 7, depicted in blue) do not induce 
these effects. In our opinion this points out a toxicodynamic distinction between LMW 





Phthalates leading to adverse antiandrogenic effects are shown to interfere with the 
steroidogenic pathways of the testes (Plummer et al., 2007). Testosterone 
biosynthesis starts from cholesterol via a multistep process involving cholesterol 
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the active steroid hormone (Thompson et al., 2004). If impacts on steroid 
biosynthesis precede the testosterone reductions leading to disrupted male 
development, the timing of steroidogenic impacts would have to be prior to the 
critical reduction in fetal testosterone that occurs during the MPW and has been 
associated with induction of TDS disorders (van den Driesche et al., 2017). The 
steroidogenic acute regulatory protein, StAR, is involved in the transport of 
cholesterol, the precursor of testosterone, in the cell into the mitochondria (Johnson 
et al., 2007). In this study, the quantitative mRNA expression of StAR, and 
ofCyp11a1 and Cyp17a1 (involved in cholesterol conversion to testosterone) was 
significantly reduced after exposure to DBP at e17.5 (P<0.05; Figure 4A-C), however 
at e21.5 this reduction had returned to control levels (Figure 4D-F). The return to 
control levels at e21.5 may reflect a rebound  after the DBP treatment window 
stopped at e18.5, which gave the fetal testes time to recover the gene expression 
levels that were measured at e21.5. In contrast, DINP did not demonstrate an impact 
on fetal testicular mRNA levels of genes involved in steroidogenesis (Cyp11a1, 
Cyp17a1) or cholesterol transport (StAR) on either e17.5 or e21.5. DINP has been 
reported in the literature to impact expression of these genes following in utero 
exposure on e14-e18 (Hannas et al., 2011, 2012). Possible differences in 
experimental design may be responsible for the different outcomes. Hannas et al., 
2011, 2012, exposed the more sensitive Sprague Dawley rats slightly longer (e14-
e18) and employed testes extraction at e18. Two other studies have also reported 
DINP-mediated effects on steroidogenesis gene expression. Adamsson et al., 2009, 
reported a statistically significant increase in Cyp11a1 and no change on StAR, 
whereas Li et al., 2015, reported a decrease in both genes. The exposure paradigms 
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7). The dose used herein was comparable to the highest dose in Adamsson et al., 
2009, while Li et al., 2015, dosed up to 1000 mg/kg bw/day. Neither Adamsson et al., 
2009, nor Li et al., 2015, observed a change in corresponding steroidogenesis 
protein levels following exposure to DINP.In the experimental model herein, the 
contrast between the outcomes of DBP, which reduces the expression of the three 
genes significantly on e17.5, and DINP, which has no effect on gene expression, 
provides compelling support that DINP does not reduce mRNA levels of 
steroidogenic genes in fetal testes during the critical MPW. 
 
The data on intratesticular testosterone levels mirrored that of the mRNA expression 
data for steroidogenesis genes. Exposure to DBP showed a statistically significant 
reduction in intratesticular testosterone at e17.5 which was maintained, however with 
lesser magnitude, at e21.5. The reduced magnitude of effect on intratesticular 
testosterone reduction at e21.5 compared to e17.5 (Figure 3C, D) is consistent with 
a rebound  effect following cessation of exposure (van den Driesche et al., 2012. 
2017). In contrast, DINP showed no effect on intratesticular testosterone at either 
timepoint (Figure 3 C, D). There are many possible explanations for why the ability of 
DINP to impact testosterone may not have been observed. A difference in androgen 
sensitivity among rat strains has been reported, with Sprague Dawley rats being 
more sensitive to steroidogenic impacts than the Wistar rat strain (Wilson et al., 
2007). However, the studies reporting a reduction in testosterone following DINP 
exposure (Borch et al., 2004; Clewell et al., 2013a; Furr et al., 2014; Hannas et al., 
2011; Li et al., 2015) versus those that do not report a dose responsive effect on 
testosterone (Adamsson et al., 2009; Boberg et al., 2011; Clewell et al., 2013b) do 
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for the lack of effect shown here. The length of time between cessation of the DINP 
exposure and the testosterone measurement could also be an important 
consideration for why no effect on testosterone was observed. Adamsson et al., 
2009, who did not detect a change in intratesticular testosterone, measured on e19.5 
following DINP exposure e13.5-17.5, proposed the rebound  effect as responsible 
for the lack of observed effect on intratesticular testosterone. The rebound  effect 
could account for the lack of effects on testosterone found in this study at GD21.5 
(Figure 3), but would not explain the lack of effect during the MPW at e17.5. Also 
note that DBP exposure during the MPW is shown here (Figure 3D) and elsewhere 
(van den Driesche et al., 2017) to reduce intratesticular testosterone days after 
exposure has ceased (although to a lesser extent). Therefore, the rebound  effect 
does not account for all of the observations in this study. DINP has been 
demonstrated to be a lower potency steroidogenesis inhibitor compared to DBP and 
other LMW phthalates to impact steroidogenesis in an ex vivo model of testicular 
testosterone production, where testes are outside of homeostatic controls for a 
period of hours before testosterone levels are assessed (Furr et al., 2014; Hannas et 
al., 2011). Therefore, the dose, duration of exposure, or nature of measurement may 
explain why no effect on testosterone was observed herein. However, taking a very 
simplistic view, studies with longer duration of exposure to higher (Boberg et al., 
2011) or comparable doses of DINP (Clewell et al., 2013b) than used here did not 
observe dose dependent changes in intratesticular testosterone; while impacts on 
intratesticular testosterone (Clewell et al., 2013a) and ex vivo testicular testosterone 
production (Hannas et al., 2011) have been reported in studies at doses lower than 
750 mg/kg bw/day. As discussed further below, an alternative explanation for our 
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does not inhibit steroidogenesis to an extent great enough to overcome homeostatic 
controls which are necessary for eliciting downstream TDS disorders. 
 
As mentioned previously, DBP has been shown to reduce intratesticular testosterone 
levels following exposure during the MPW (e15.5-18.5) as well as following exposure 
after the MPW (e19.5-20.5), however, the fetal testosterone deficiency induced after 
the MPW is not associated with induction of TDS disorders (van den Driesche et al., 
2017). Therefore, the timing of androgen reduction matters. The studies that assess 
effects of DINP on male reproductive tract development intertwine the evaluation of 
effects mediated during the MPW (i.e. programming event) with those that are 
initiated or impacted later in development due to the duration of the exposures 
employed (see Figure 7). Interpretation of these data is further complicated by a lack 
of standardization of what developmental time point measurements are taken. 
Interpreting the meaning of reported outcomes on DINP without carefully considering 
the dynamics and temporality of biology during fetal development confounds 
interpretation and may be obscuring the meaning of reported observations. None of 
the existing studies on DINP (Figure 7) limited exposure to the MPW only, nor 
measured intratesticular testosterone during the MPW. The absence of a DINP-
mediated effect on intratesticular testosterone levels on e17.5 observed herein, is 
consistent with the body of evidence reporting a lack of induction of gross male 
reproductive tract malformations such as cryptorchidism and hypospadias following 
DINP exposures (Boberg et al., 2011; Clewell et al., 2013b; Gray et al., 2000). 
Absence of an impact on testosterone at e17.5 and e21.5 following exposure during 
the MPW is also consistent with the body of evidence indicating DINP does not 
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a shortened AGD serves as a useful correlative biomarker for reduced fetal 
androgen levels in the MPW (Schwartz et al., 2019; Welsh et al., 2008; van den 
Driesche et al., 2017). The majority of studies on DINP report no statistically 
significant change on AGD following in utero exposure (Clewell et al., 2013a; Gray et 
al., 2000; Li et al., 2015; Masutomi et al., 2003). Of the two studies that report a 
statistically significant finding, Boberg et al., 2011, reported a small but statistically 
significant AGD decrease in males exposed to 900 mg/kg bw/day DINP. The 
biological and toxicological relevance of this reported finding are questionable 
however, due to the small magnitude (~5%) of the change, reported challenges in 
reproducing the statistical significance upon reanalysis of the raw data (Chen et al., 
2017), and published methodology modifications (Boberg et al., 2016) indicating 
AGD was measured by different technicians on different days (as rapid pup growth 
and technician variability can affect AGD measurements, randomization of animals 
across days and technicians is important for informing significance of outcomes). 
Clewell et al., 2013b, reported a statistically significant decrease of AGD (both 
scaled for body weight and absolute) on postnatal day 14 at the highest DINP dose 
(11,400 ppm), but not at postnatal days 2 and 49. AGD is highly dependent on 
animal size, and the postnatal day 14 animal weights for males in this dose group 
were also statistically different than controls. Given that anogenital differences 
induced by anti-androgenic influences in utero should be apparent at birth, the 
difference observed at postnatal day 14 without a correlative difference at postnatal 
day 2 suggest the postnatal day 14 observation was unlikely due to an anti-
androgenic effect. The findings reported here that DINP does not impact 
testosterone levels on e17.5 add more collective weight to the conclusion that DINP 
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4.3. Leydig cell aggregates 
As expected from the results of a previous study with 500 mg/kg bw/day (van den 
Driesche et al., 2012), in utero exposure to 750 mg/kg bw/day DBP resulted in 
statistically significant decreases in small and increases in large Leydig cell 
aggregates on both time points (e17.5 and e21.5) compared to controls. However, in 
contrast with DBP, in utero exposure to DINP did not result in any significant 
differences in the percentage of small or large Leydig cell aggregates when compared 
with vehicle control exposed animals (Figure 6C, D). The relevance of the small, but 
significant effect noted when comparing the 125 to the 750 mg/mg bw/day DINP 
exposure group at e21.5 remains unclear. This reduction in small and the 
corresponding increase in large fetal Leydig cell clusters at e21.5 could also be within 
the variation of the method used (Figure 6D). 
 
4.4 Effects on Sperm 
The findings reported herein are similar to those in previous studies on DINP 
reporting a lack of statistically significant or dose-related effects of DINP on testicular 
descent, penile development and AGD in adult animals following in utero exposure 
to DINP during the MPW (Boberg et al., 2011; Clewell et al., 2013b; Gray et al., 
2000). Neither the current study (Figure 2) nor the study by Boberg et al., 2011, 
found an effect on sperm count in adult males (see also Chen et al., 2017 for 
reanalysis of the statistics reported in Boberg et al., 2011). In contrast, no effect was 
observed on sperm motility in this study, whereas Boberg et al., 2011 reported a 
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sperm motility in the untreated controls did not reach the minimum value of 70% 
motility which OECD (Guidance Document No. 43, 2008; Seed et al., 1996). A key 
difference in our study design is the window of exposure. We stopped exposure at 
e18.5 whereas Boberg et al., 2011, extended the exposure window to postnatal day 
17. Exposure to DBP during the MPW alone is shown herein to be sufficient to 
impact sperm count and motility (Figure 2 C, D). However, considering the timeline 
for germ cell development and postnatal development of sperm, timing of exposure 
could be important for explaining the differences seen with DINP between studies. 
For example, during normal testis development at e21.5 germ cells are migrating 
outwards to gain contact with basal lamina where they differentiate into 
spermatogonia. As shown by Lara et al., 2017, DBP shows a much greater 
disruption of this migration and increased germ cell aggregation following exposure 
from e19.5-20.5 or e13.5-20.5, with significantly more germ cells migrating and 
reduced aggregation observed following exposure during the MPW alone. This is 
consistent with germ cell aggregation being an effect induced later in gestation, 
supporting that timing of exposure as possibly important for detecting effects on 
sperm. Considering the low percentage of motile sperm in the controls of the Boberg 
et al., 2011, study, the known sensitivity of sperm to experimental conditions (Seed, 
et al., 1996) and importance of optimized computer assisted counting measurements 
(Schleh et al, 2013), it is also possible that the reported outcomes by Boberg et al., 
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5. Conclusion 
Overall, the results of this systematic comparison provide convincing evidence on 
the differences between the effects occurring with the LMW DBP (positive control) 
and the HMW DINP. In contrast to what was seen with DBP, DINP did not cause 
cryptorchidism or hypospadias. There was no effect on AGD/AGi. Leydig cell 
aggregates on e17.5 and e21.5 did not increase. There was no reduction of 
intratesticular testosterone, no effects on sperm motility and sperm count and no 
effects on adult testosterone and LH levels were seen. In this experimental model, 
DINP does not cause adverse reproductive effects and endocrine effects like DBP. 
Our findings are similar to those in previous studies on DINP reporting a lack of 
statistically significant or dose-related effects of DINP on testicular descent, penile 
development and AGD in adult animals following in utero exposure to DINP during 
the MPW (Boberg et al. 2011; Clewell et al., 2013b; Gray et al., 2000). 
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Table 1: Structures and abbreviations of phthalates in this study 
Chemical Name Abbreviation CAS No Structure 
Dibutyl phthalate DBP 84-74-2 
 
















Table 2. Effects of in utero exposure to vehicle control, 750 mg/kg bw/day DBP (DBP-750), 125 
mg/kg bw/day DINP (DINP-125) and 750 mg/kg bw/day DINP (DINP-750) from e15.5-18.5 on 
adult reproductive phenotype 
 Control DBP-750 DINP-125 DINP-750 
Body weight (g) 408.03 ± 9.70 383.30 ± 11.38 399.23 ± 6.90 417.97 ± 4.64 
AGD (mm) 44.80 ± 0.94 35.67 ± 1.48 a 43.598 ± 0.55 44.36 ± 0.44 
Anogenital index 6.04 ± 0.09 4.91 ± 0.19 a 5.92 ± 0.08  5.93 ± 0.05 
Average testis 
weight (g) 
1.96 ± 0.04 0.97 ± 0.13 a 1.99 ± 0.02 1.94 ± 0.04 
Penis length (mm) 10.94 ± 0.22 9.17 ± 0.21 a 10.66 ± 0.07 10.51 ± 0.19 
Penis weight (g) 0.148 ± 0.006 0.109 ± 0.004 a 0.138 ± 0.003 0.134 ± 0.005 
Ventral prostrate 
weight (g) 
0.48 ± 0.03 0.40 ± 0.02 a 0.49 ± 0.03 0.49 ± 0.02 
Seminal vesicle 
weight (g) 
0.73 ± 0.03 0.33 ± 0.03 a 0.71 ± 0.02 0.69 ± 0.03 
Results are expressed as litter means ± SEM. n = 7 for control, DINP 125 mg/kg bw/day and 
DINP 750 mg/kg bw/day groups, and n = 6 for the DBP 750 mg/kg bw/day group. 







Figure 2. In utero exposure to Dibutyl phthalate (DBP, 750 mg/kg bw/day) in the masculinisation programming window (e15.5-e18.5), but not to low (125 
mg/kg bw/day) or high (750 mg/kg bw/day) doses of Diisononyl phthalate (DINP) induces TDS-like symptoms in adulthood. Values are Litter Means ± SEM 
(n = 7 for control, n=6 for DBP-750, n = 7 for DINP-125, n=7 for DINP-750). *p<0.05, ***p<0.001 in comparison with respective controls. 




Figure 3. In utero exposure to Dibutyl phthalate (DBP, 750 mg/kg bw/day) in the masculinisation programming window, but not to low (125 mg/kg bw/day) 
or high (750 mg/kg bw/day) doses of Diisononyl phthalate (DINP) induces effects on testosterone and anogenital distance (AGD) in male fetuses. Effects 
from in utero exposure vehicle (Control), DBP (750 mg/kg bw/day), DINP (125 or 750 mg/kg bw/day) on (A) AGD at e21.5 (Values are Litter Means ± SEM 
n = 7 for control, n=6 for DBP-750, n = 6 for DINP-125, n = 6 for DINP-750 ), (B) average testis weight at e21.5 (Values are Litter Means ± SEM n = 7 for 
control, n=6 for DBP-750, n = 6 for DINP-125, n = 6 for DINP-750), (C), intratesticular testosterone at e17.5 (Values are Litter Means ± SEM n = 7 for control, 
n=6 for DBP-750, n = 6 for DINP-125, n = 6 for DINP-750, and (D) intratesticular testosterone at e21.5 (values are Litter Means ± SEM (n = 4 for control, 
n=7 for DBP-750, n = 4 for DINP-125, n = 6 for DINP-750 at e17.5). ***p<0.001 in comparison with respective controls. 
Click he e  acce /d l ad;Fig e;Fig e 3.d c
 
Figure 4. Quantitative mRNA expression of steroidogenic genes in e17.5 and e21.5 testes after exposure to vehicle (Control), Dibutyl phthalate 
(DBP-750 mg/kg bw/day), Diisononylphthalate (DINP-125 or 750 mg/kg bw/day). (A, D) Steroidogenic acute regulatory protein (StAR), (B, E) 
cytochrome P450, family 11, subfamily a, polypeptide 1 (Cyp11a1), (C, F) cytochrome P450, family 17, subfamily a, polypeptide 1 (Cyp17a1).  
Dams were exposed from embryonic day (e) 15.5-17.5 (A-C) or e15.5-18.5 (D-F). Values are Litter Means ± SEM (n = 3 litters per treatment 
group). *p<0.05 in comparison with respective controls. 




Figure 5. Triple immunofluorescense labelling of fetal testes at e21.5 following exposure during 
the male programming window to vehicle (Control), Dibutyl phthalate (DBP-750 mg/kg bw/day), 
Diisononylphthalate (DINP- 125 or -750 mg/kg bw/day. 
3 -HSD (green; fetal Leydig cell marker), Sox-9 ( ed; Se i ce  a e ), SMA (b e; -smooth 
muscle actin, peritubular myoid cell marker). The asterisk in panel B illustrates focal dysgenesis in 
the DBP 750 mg/kg bw/day (DBP-750) treatment group. Scale bar = 200 µm. 




Figure 6: Quantitative evaluation of Leydig cell aggregates in e17.5 and e21.5 testes after 
exposure during the male programming window (MWP) to vehicle (Control), Dibutyl phthalate (DBP, 
750 mg/kg bw/day), Diisononylphthalate (DINP, 125 or 750 mg/kg bw/day). 
(A) Schematic diagram to illustrate the collection of the sections at 25, 50 and 75%, which were 
included in the systematic analysis in order to get a representative average for each testis. 
(B) Examples of the immunostaining with 3β-HSD (1st row), corresponding transformed, 
background corrected pictures for automatic counting (2nd row). For technical details see the 
Materials and Methods. 
Click he e  acce /d l ad;Fig e;Fig e 6.d c
 
 
(C) Quantitative Assessment of Leydig cell aggregates. Values are Litter Means ± SEM (n = 6 for 
control, n=6 for DBP 750 mg/kg bw/day (DBP-750), n = 6 for DINP 125 mg/kg bw/day (DINP-125), 
n = 5 for DINP 750 mg/kg bw/day (DINP-750) at e17.5 and e21.5). *p<0.05 when DINP-125 and 
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Figure 7. Developmental Toxicity Studies with DINP. The duration and timing of exposure for published studies on DINP are depicted here in relation to 
select male rat developmental milestones. Studies involving exposures encompassing the male programming window (MPW) are depicted in green. 
Studies involving exposure prior to the MPW are depicted in blue. # denotes study was performed in Wistar rats; * denotes study was performed in 




Figure 1: Study design: Indicated with blue arrows are testis differentiation in the rat (starting at embryonic day e13.5 and reproductive tract differentiation 
(from e18.5 onwards). The masculinisation programming window (MPW, e15.5–e18.5) is indicated with the blue box. Three different experiments were 
performed. The treatment window that was used in the two fetal studies was during the MPW, from e15.5–e17.5 for e17.5 fetal isolations; and from e15.5-
e18.5 for e21.5 fetal isolations. The following observations were made: anogenital distance (AGD) was measured (in e21.5 fetal isolations only), testes 
were dissected and weighed (testes of e17.5 fetal isolations were not weighed), 1 testis was fixed for subsequent immunohistochemistry and 1 testis was 
frozen on dry ice for subsequent intratesticular testosterone (ITT) measurement. In a third experiment, pregnant rats were treated from e15.5–e18.5 and 
male animals were collected in adulthood at postnatal day (pnd) 90. Blood was taken for hormone measurements, the animals were phenotypically analysed, 
sperm motility was determined and testis samples were collected for sperm head counts. 
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